Immune Checkpoint Inhibitors in AML-A New Frontier
-
Published:2020-08-11
Issue:7
Volume:20
Page:545-557
-
ISSN:1568-0096
-
Container-title:Current Cancer Drug Targets
-
language:en
-
Short-container-title:CCDT
Author:
Thummalapalli Rohit1, Knaus Hanna A.2, Gojo Ivana3, Zeidner Joshua F.4
Affiliation:
1. Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, United States 2. Medical University of Vienna, Department of Medicine, Division of Bone Marrow Transplantation and Cellular Therapies, Vienna, Austria 3. Department of Medical Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States 4. University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States
Abstract
Despite recent therapeutic advancements, acute myeloid leukemia (AML) remains a challenging
clinical entity with overall poor outcomes. Given the evident role of T cell-mediated immunity
in response to allogeneic stem cell transplantation and donor lymphocyte infusions, strategies
that enhance immune activation and mitigate immune dysfunction represent attractive therapeutic
platforms to improve clinical outcomes in AML. Pre-clinical data suggest that immune dysfunction
is a major contributor to AML progression and relapse. Increased expression of immune checkpoints
such as programmed death 1 (PD-1) contributes to AML immune evasion and is associated with disease
progression. Immune checkpoint inhibition is being explored in AML with early evidence of
clinical activity, particularly in combination with cytotoxic chemotherapy and hypomethylating
agents. In this review, we explore the scientific rationale behind the use of immune checkpoint inhibition
either as single agents or in combination with hypomethylating agents or cytotoxic chemotherapy
and provide a clinical update of both completed and ongoing trials in AML.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Drug Discovery,Pharmacology,Oncology
Reference95 articles.
1. Schmid,C.; Labopin,M.; Nagler,A.; Niederwieser,D.; Castagna,L.; Tabrizi,R.; Stadler,M.; Kuball,J.; Cornelissen,J.; Vorlicek,J.; Socié, G.; Falda,M.; Vindeløv,L.; Ljungman,P.; Jackson,G.; Kröger,N.; Rank,A.; Polge,E.; Rocha,V.; Mohty, M. Acute Leu-kaemia Working Party of the European Group for Blood and Ma-rrow Transplantation (EBMT) . Treatment, risk factors, and outco-me of adults with relapsed AML after reduced intensity conditio-ning for allogeneic stem cell transplantation. Blood. 2012,119(6),1599-1606. http://dx.doi.org/10.1182/blood-2011-08-375840 PMID: 22167752 2. Döhner,H.; Estey, E.H.; Amadori,S.; Appelbaum, F.R.; Büchner,T.; Burnett, A.K.; Dombret,H.; Fenaux,P.; Grimwade,D.; Larson, R.A.; Lo-Coco,F.; Naoe,T.; Niederwieser,D.; Ossenkoppele, G.J.; Sanz, M.A.; Sierra,J.; Tallman, M.S.; Löwenberg,B.; Bloomfield, C.D. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an internatio-nal expert panel, on behalf of the European LeukemiaNet. Blood. 2010,115(3),453-474. http://dx.doi.org/10.1182/blood-2009-07-235358 PMID: 19880497 3. Postow, M.A.; Chesney,J.; Pavlick, A.C.; Robert,C.; Grossmann,K.; McDermott,D.; Linette, G.P.; Meyer,N.; Giguere, J.K.; Agar-wala, S.S.; Shaheen,M.; Ernstoff, M.S.; Minor,D.; Salama, A.K.; Taylor,M.; Ott, P.A.; Rollin, L.M.; Horak,C.; Gagnier,P.; Wol-chok, J.D.; Hodi, F.S. Nivolumab and ip ilimumab versus ipilimu-mab in untreated melanoma, N. Engl, J. Med. 2015,372(21),2006-2017. http://dx.doi.org/10.1056/NEJMoa1414428 PMID: 25891304 4. Postow, M.A.; Callahan, M.K.; Wolchok, J.D. Immune Checkpoint Blockade in Cancer Therapy, J. Clin. Oncol. 2015,33(17),1974-1982. http://dx.doi.org/10.1200/JCO.2014.59.4358 PMID: 25605845 5. Ansell, S.M.; Lesokhin, A.M.; Borrello,I.; Halwani,A.; Scott, E.C.; Gutierrez,M.; Schuster, S.J.; Millenson, M.M.; Cattry,D.; Freeman, G.J.; Rodig, S.J.; Chapuy,B.; Ligon, A.H.; Zhu,L.; Grosso, J.F.; Kim, S.Y.; Timmerman, J.M.; Shipp, M.A.; Armand, P. PD-1 blockade with nivolumab in relapsed or refractory Hodg-kin’s lymphoma, N. Engl, J. Med. 2015,372(4),311-319. http://dx.doi.org/10.1056/NEJMoa1411087 PMID: 25482239
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|